In my father’s printing shop in Bologna, we understood that a page is only as reliable as the press that produces it. If the machine is misaligned, the truth becomes a smudge.
By Elena Rossi ·
While individualized mRNA vaccines show immense promise for cancer, their economic viability and operational scaling remain massive hurdles.
By Grant Colby ·
The market’s reaction to Moderna and Merck's personalized mRNA vaccine for melanoma—a spectacular 177% surge in Moderna’s stock, according to CNBC—is pure adrenaline.
By Dana Whitfield ·
The sheer velocity of the stock market is always the most exhausting part of any major announcement.
By Aoife Gallagher ·
I’ve spent my life scoring things in payroll. I track whether a promise lands on a spreadsheet: who gets hired, at what wage, and if the work remains there five years from now.
By Ray Dombrowski ·
The whole performance around flu shots feels less like public health advice and more like an exercise in regulatory theater.
By Ray Dombrowski ·
The details are always the same when Washington decides to play God with basic medicine. First, there’s the technological breakthrough—in this case, Moderna's mFlusiva, an mRNA-based flu vaccine.
By Grant Colby ·
The news cycle has an alarming habit: when a deadly pathogen flares up in the Global South, the response is not measured competence but breathless technological pronouncements.
By Klaus Berger ·